Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113793 | 0.86 | MAPT (0.65) | GAAMAPTALDH1A1RXFP1KMT2A | |
| SCHEMBL5336131 | 0.86 | PTPN1 (0.64) | GAAMAPTPTPN1ALDH1A1KDM4E | |
| SCHEMBL10153183 | 0.85 | GAA (0.56) | GAAMAPTTDP1RXFP1KMT2A | |
| SCHEMBL14248201 | 0.84 | GAA (0.55) | GAAMAPTTDP1RXFP1KMT2A | |
| SCHEMBL6563525 | 0.80 | CACNA1F (0.60) | GAAPTPN1ALDH1A1KDM4EKMT2A | |
| SCHEMBL2267031 | 0.79 | GAA (0.50) | GAAMAPTTDP1RXFP1KMT2A | |
| SCHEMBL2567142 | 0.79 | ALDH1A1 (0.58) | GAAMAPTTDP1ALDH1A1KDM4E | |
| SCHEMBL4503574 | 0.79 | ALDH1A1 (0.58) | GAAMAPTTDP1ALDH1A1KDM4E | |
| SCHEMBL13118736 | 0.78 | TDP1 (0.57) | GAAMAPTTDP1ALDH1A1KDM4E | |
| SCHEMBL28521809 | 0.77 | PTPN1 (0.45) | GAAMAPTPTPN1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174898-B | Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone | 浙江宏元药业股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112174898-A | Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone | 浙江宏元药业股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | GAA 347/4885MAPT 1208/4885PTPN1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.